FIELD: pharmaceuticals.
SUBSTANCE: invention relates to compounds of general formula I or to their pharmaceutically acceptable salts in which the radicals and symbols are defined in the claims. Compounds of formula I inhibit Btk and can be used to modulate Btk activity and treat diseases associated with excessive Btk activity. Also pharmaceutical composition is disclosed comprising the compounds of Formula I and at least one carrier, diluent or excipient.
(I).
EFFECT: compounds can be used to treat cancer, autoimmune and inflammatory diseases caused by aberrant B cell activation.
20 cl, 59 ex, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| BRUTON'S TYROSINE KINASE INHIBITORS | 2014 |
|
RU2653500C2 |
| BRUTON'S TYROSINE KINASE INHIBITORS | 2014 |
|
RU2653504C2 |
| AMINOPYRAZOLE DERIVATIVE | 2010 |
|
RU2580543C9 |
| COMT INHIBITORS | 2013 |
|
RU2642779C2 |
| PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | 2016 |
|
RU2729609C2 |
| PHENOXYMETHYL DERIVATIVES | 2016 |
|
RU2746481C1 |
| PYRROLOPYRAZINE KINASE INHIBITORS | 2012 |
|
RU2673064C2 |
| HETEROCYCLIC DERIVATIVES AS RECEPTORS ASSOCIATED WITH TRACER AMINES (TAARS) | 2013 |
|
RU2621050C2 |
| INDOL-3-YL-CARBONYL-PIPERADINE-BENZIMIDAZOLE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | 2006 |
|
RU2415139C2 |
| PYRROL[2,3-B]PYRAZINES AS SYK INHIBITORS | 2013 |
|
RU2656853C2 |
